Equipment maker Terex Q2 sales beat estimates, lifts FY outlook
Reuters2026/07/30 11:21
Overview
U.S. specialized equipment maker's Q2 sales rose 50.5%, beating analyst expectations
Adjusted EPS for Q2 was $1.37
Company raised 2026 outlook on improved backlog and operational momentum
Outlook
Terex raises 2026 sales outlook to $7.9 bln-$8.2 bln
Company expects 2026 adjusted EBITDA of $960 mln-$1 bln
Terex sees 2026 adjusted EPS of $4.70-$5.10
Result Drivers
SEGMENT GROWTH - Sales increased in all segments, with Materials Processing and Specialty Vehicles highlighted as key contributors
DEMAND DRIVERS - Increased demand for mobile crushers in the U.S. and higher shipments of fire apparatus and utilities products supported segment growth
MARGIN PRESSURE - Profitability in some segments was affected by inflation, tariffs, and production ramp-up inefficiencies
Company press release: ID:nPn4zwkkla
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
Q2 Sales |
Beat |
$2.20 bln |
$2.14 bln (11 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 5 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the heavy machinery vehicles peer group is "buy"
Wall Street's median 12-month price target for Terex Corp is $80.00, about 23.9% above its July 29 closing price of $64.56
The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 12 three months ago
Reuters Recommended Reads
July 28 - Oshkosh Q2 profit beats on improved pricing
July 28 - Crane Company Q2 sales rise 26%, beat estimates; outlook raised
July 29 - IDEX lifts annual profit outlook after upbeat second quarter on strong AI data center demand
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
FDA grants priority review to Genentech’s Enspryng for MOGAD
2-Yr Benchmark Govt Yields - U.S. vs Other Nations
10-Yr Benchmark Govt Yields - Germany vs Other Nations